Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence

Neuropathology

Volumn 31, Issue 6, 2011, Pages 575-582

  Idoate, Miguel Angel ^a   Díez Valle, Ricardo ^b   Echeveste, Jose ^a   Tejada, Sonia ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

5 aminolevulinic; Acute glia; Glioblastoma; Invasive tumor; Nestin; Tumor border

Indexed keywords

AMINOLEVULINIC ACID; KI 67 ANTIGEN; NESTIN;

ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; FLUORESCENCE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR;

AMINOLEVULINIC ACID; BRAIN NEOPLASMS; FLUORESCENT DYES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; NERVE TISSUE PROTEINS;

EID: 81955160890     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2011.01202.x     Document Type: Article

References (33)

1. Lacroix M, Abi-Said D, Fourney DR etal. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95 (Suppl 2): 190-198.
2. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62 (Suppl 4): 753-764; discussion 264-6.
3. Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen HJ. Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 1998; 140 (Suppl 10): 995-1000.
4. Stummer W, Pichlmeier U, Meinel T etal. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7 (Suppl 5): 392-401.
5. Stummer W, Reulen HJ, Meinel T etal. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62 (Suppl 3): 564-576; discussion 564-76.
6. Gaspar LE, Fisher BJ, Macdonald DR etal. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992; 24 (Suppl 1): 55-57.
7. Singh SK, Clarke ID, Terasaki M etal. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63 (Suppl 18): 5821-5828.
8. Hockfield S, McKay RD. Identification of major cell classes in the developing mammalian nervous system. J Neurosci 1985; 5 (Suppl 12): 3310-3328.
9. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell 1990; 60 (Suppl 4): 585-595.
10. Dahlstrand J, Zimmerman LB, McKay RD, Lendahl U. Characterization of the human nestin gene reveals a close evolutionary relationship to neurofilaments. J Cell Sci 1992; 103 (Suppl Pt 2): 589-597.
11. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992; 52 (Suppl 19): 5334-5341.
12. Maderna E, Salmaggi A, Calatozzolo C, Limido L, Pollo B. Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther 2007; 6 (Suppl 7): 1018-1024.
13. Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007; 68 (Suppl 2): 133-143; discussion 143-4.
14. Chinnaiyan P, Wang M, Rojiani AM etal. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the radiation therapy oncology group. Radiat Oncol 2008; 3: 32.
15. Bexell D, Gunnarsson S, Siesjo P, Bengzon J, Darabi A. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. Int J Cancer 2009; 125 (Suppl 1): 15-22.
16. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol 2008; 90 (Suppl 2): 157-170.
17. Loja T, Chlapek P, Kuglik P etal. Characterization of a GM7 glioblastoma cell line showing CD133 positivity and both cytoplasmic and nuclear localization of nestin. Oncol Rep 2009; 21 (Suppl 1): 119-127.
18. Rieske P, Golanska E, Zakrzewska M etal. Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors. BMC Cancer 2009; 9: 54.
19. Zhang M, Song T, Yang L etal. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008; 27: 85.
20. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000; 93 (Suppl 6): 1003-1013.
21. Valle R, Solis S, Idoate Gastearena MA, de Eulate R, Echvarri P, Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol 2010; July 6 (Epub ahead of print) DOI: 10.1007/s11060-010-0296-4.
22. Stummer W, Stocker S, Wagner S etal. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42 (Suppl 3): 518-525; discussion 525-6.
23. Kelly PJ. Computed tomography and histologic limits in glial neoplasms: tumor types and selection for volumetric resection. Surg Neurol 1993; 39 (Suppl 6): 458.
24. Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007; 6 (Suppl 7): 1909-1919.
25. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21 (Suppl 8): 1624-1636.
26. Hoelzinger DB, Mariani L, Weis J etal. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005; 7 (Suppl 1): 7-16.
27. Mangiola A, de Bonis P, Maira G etal. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 2008; 113 (Suppl 4): 841-846.
28. Dalrymple SJ, Parisi JE, Roche PC, Ziesmer SC, Scheithauer BW, Kelly PJ. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 1994; 35 (Suppl 6): 1036-1044; discussion 1044-5.
29. Duggal N, Schmidt-Kastner R, Hakim AM. Nestin expression in reactive astrocytes following focal cerebral ischemia in rats. Brain Res 1997; 768 (Suppl 1-2): 1-9.
30. Frisen J, Johansson CB, Torok C, Risling M, Lendahl U. Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. J Cell Biol 1995; 131 (Suppl 2): 453-464.
31. Krum JM, Rosenstein JM. Transient coexpression of nestin, GFAP, and vascular endothelial growth factor in mature reactive astroglia following neural grafting or brain wounds. Exp Neurol 1999; 160 (Suppl 2): 348-360.
32. Tamagno I, Schiffer D. Nestin expression in reactive astrocytes of human pathology. J Neurooncol 2006; 80 (Suppl 3): 227-233.
33. Mangiola A, Lama G, Giannitelli C etal. Stem cell marker nestin and c-jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 2007; 13 (Suppl 23): 6970-6977.